Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Pediatric Hematology/Oncology
•
Clinical Trials
•
Pediatric Oncology
•
Oncology
What are the main barriers you encounter in enrolling pediatric oncology patients on clinical trials?
Related Questions
Which oral chemotherapy regimen do you use in relapsed fusion positive rhabdomyosarcoma?
What is your approach to patients/parents seeking alternative or complementary treatment in pediatric oncology patients?
How do you approach revaccination after chemotherapy, and what labs (if any) do you use to assess immune reconstitution?
How do you determine timing, and whether or not to rechallenge a pediatric oncology patient with immune checkpoint inhibitor therapy after development of irAE?
For what patients/diagnoses do you currently use sodium thiosulfate to reduce the risk of cisplatin associated ototoxicity?
How do you incorporate psychological care into the surveillance and treatment of a pediatric patient found to have a cancer predisposition syndrome?
When do you consider altering treatment for a patient with metastatic osteosarcoma who showed poor response to upfront therapy with MAP (doxorubicin, cisplatin, methotrexate) chemotherapy?
In platinum-refractory or multiply-relapsed NSGCT with 1–2 progressive sites and no good surgical option, is there a role for local radiotherapy (e.g., SBRT) to those sites?
Do you routinely use thrombopoietin receptor agonists (like romiplostim) to address chemotherapy-induced thrombocytopenia in solid tumor pediatric oncology patients?
What is your typical surveillance imaging for a pediatric patient with history of treated sarcoma off therapy?
